Cliniphar (TSE:432A) EBITDA Margin %: 5.04% (As of Mar. 2026) — Near Median


TSE:432A Cliniphar Ltd TSE:432A
20 GF Score
Price 円1,450.00
! 3 Warning Signs
View Full Analysis

What is Cliniphar EBITDA Margin %?

Cliniphar TSE:432A 20 EBITDA Margin % is 5.04% as of Mar. 2026, which is at its 10-year median of 5.04. GuruFocus rates TSE:432A with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cliniphar's EBITDA for the six months ended in Mar. 2026 was 円187 Mil. Cliniphar's Revenue for the six months ended in Mar. 2026 was 円3,701 Mil. Therefore, Cliniphar's EBITDA margin for the quarter that ended in Mar. 2026 was 5.04%.

Cliniphar  (TSE:432A) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Cliniphar EBITDA Margin % Related Terms

Cliniphar EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Cliniphar's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cliniphar EBITDA Margin % Chart

Cliniphar Annual Data
Trend Mar24 Mar25 Mar26
EBITDA Margin %
-14.32 6.68 5.04

Cliniphar Semi-Annual Data
Mar24 Mar25 Mar26
EBITDA Margin % -14.32 6.68 5.04

Cliniphar EBITDA Margin % Competitor Comparison

For the Pharmaceutical Retailers subindustry, Cliniphar's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cliniphar EBITDA Margin % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cliniphar's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Cliniphar's EBITDA Margin % falls into.


TSE:432A
20GF Score
Cliniphar Ltd TSE:432A
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cliniphar EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Cliniphar's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=186.678/3700.714
=5.04 %

Cliniphar's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=186.678/3700.714
=5.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 5.04% mean?
Cliniphar (TSE:432A) has a EBITDA Margin % of 5.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cliniphar and its competitors. This is near median its historical median of 5.04.
Is Cliniphar's EBITDA Margin % too high?
Cliniphar's current EBITDA Margin % of 5.04% is near median its 10-year median of 5.04. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. Cliniphar's value of 5.04% is 50.8% below this industry median. Overall, Cliniphar has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Cliniphar's EBITDA Margin % compare to competitors?
Cliniphar's EBITDA Margin % of 5.04% can be compared against companies in the Healthcare Providers & Services industry. The industry median EBITDA Margin % is 10.24. Cliniphar's value of 5.04% is 50.8% below this benchmark. While the company's 10-year median is 5.04 vs. the industry median of 10.24, Cliniphar has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cliniphar's current EBITDA Margin % of 5.04% is 50.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cliniphar and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cliniphar's current EBITDA Margin % is 5.04%, which is near median its own 10-year median of 5.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cliniphar stock overvalued right now?
Cliniphar (TSE:432A) has a current EBITDA Margin % of 5.04%. The current EBITDA Margin % is 5.04%, which is near median its 10-year median of 5.04 and 50.8% below the Healthcare Providers & Services industry median of 10.24. Cliniphar's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cliniphar (TSE:432A), the current EBITDA Margin % is 5.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cliniphar Business Description

Address 1-7-31, Otemae, 5th Floor, OMM Building, Otemae, Chuo-ku, Osaka-shi, Osaka, JPN, 540-0008
Cliniphar Ltd is engaged in Pharmaceutical Wholesale and Distribution Business for Domestic and International Markets.
20GF Score

Get the complete analysis for TSE:432A

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,450.00
Price